Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

January 31, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

December 23, 2019

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

News Daily News

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

July 02, 2019

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Industry News

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

May 06, 2019

News Features

Year in Review: Physicians Pick the Biggest News of 2018

TCTMD News Team

December 29, 2018

Top News in Structural Heart Disease: 2018

News Features

Top News in Structural Heart Disease: 2018

December 28, 2018

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

September 14, 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.